Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
118 hedge funds and large institutions have $213M invested in Cymabay Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 17 closing their positions.
77% more call options, than puts
Call options by funds: $805K | Put options by funds: $456K
52% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 25
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
4% more funds holding
Funds holding: 113 → 118 (+5)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
1% less capital invested
Capital invested by funds: $216M → $213M (-$2.47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$1M |
| 2 |
Millennium Management
New York
|
+$950K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$883K |
| 4 |
Renaissance Technologies
New York
|
+$768K |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$653K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.3M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.01M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$663K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$361K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$334K |
CBAY Hedge Fund Activity: Q1 2022 in Review
118 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2022, worth a combined $213M — down 1.1% from $216M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CBAY positions and 17 closed out — a net gain of 5 holders — while 38 added to existing stakes and 25 trimmed.
The largest buyer was Commodore Capital, adding an estimated $1M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.3M sold.
- 118 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2022, up from 113 in Q4 2021.
- Funds reported $213M of Cymabay Therapeutics stock for Q1 2022, down 1.1% quarter-over-quarter.
- 22 funds opened new Cymabay Therapeutics positions in Q1 2022 and 17 closed out, a net change of +5 holders.
- The largest Cymabay Therapeutics buyer in Q1 2022 was Commodore Capital, an estimated $1M added.
- The largest Cymabay Therapeutics seller in Q1 2022 was Point72 Asset Management, an estimated $2.3M sold.
Based on aggregated 13F filings for Q1 2022.